Search This Blog

Monday, August 15, 2011

Targeting the Phosphoinositide-3 Kinase (PI3K) Pathway in Breast Cancer

This podcast reviews current data related to the phosphoinositide-3 kinase (PI3K) pathway, its role in breast cancer, the frequently with which PI3K is aberrant in breast cancer, and the potential clinical implications of using agents that target the PI3K pathway. Jose Baselga is the Chief of the Division of Hematology/Oncology and Associate Director of the Massachusetts General Hospital Cancer Center in Boston where he is also Professor of Medicine at Harvard Medical School. His research interests are in clinical breast cancer and in translational and early clinical research. He conducted the initial clinical trials with the monoclonal antibodies cetuximab and trastuzumab and is leading the clinical development of several new agents including pertuzumab and PI3K inhibitors. His main focus in the laboratory and in the clinic is in the area of novel anti-HER2 agents, in the identification of mechanisms of resistance to anti-HER2 agents and therapeutic approaches to target the PI3K pathway. He is also leading a number of neo-adjuvant trials in breast cancer and has been at the forefront of developing biomarker-based early and translational clinical trials.



No comments:

Post a Comment